FABP4 and cancer: Pretreatment with mifepristone, a glucocorticoid receptor antagonist [59], significantly inhibited the increase in the expression levels of aP2 and PPARγ in ST2 cells treated with the serum derived from LLC-bearing cancer cachectic mice under the adipogenic differentiation condition (Figure 4h,i).